Disease Clusters?
Groups of diseases that share a large number of curated genes with each other, computed via label propagation over the shared-gene similarity graph. See also Shared-Gene Disease Pairs for pairwise comparisons.
← Back to all clusters
Cluster 294
6
Diseases
26
Unique genes
0.197
Avg. similarity score
Bonnevie-ullrich syndrome
Most-connected disease (5 links)
Disease
Pinned (dragged)
Node size = connections within this cluster · edge thickness = similarity strength · hover an edge for its details ·
click a node to select it and show its pairs below (double-click or Ctrl/⌘-click opens the disease page) ·
drag a node to pin it in place · scroll/pinch to zoom.
Bonnevie-ullrich syndrome
Turner syndrome
Ureteral calculi
Acatalasia
Aortic disease
amyotrophic lateral sclerosis type 1
Member diseases (most connected first ‐ the cluster's core)
| Disease ⇵ | Connections in cluster ⇵ | Significant partners ⇵ | Curated genes ⇵ |
|---|---|---|---|
| Bonnevie-ullrich syndrome | 5 | 5 | 7 |
| Turner syndrome | 5 | 5 | 8 |
| Ureteral calculi | 5 | 5 | 4 |
| Acatalasia | 3 | 3 | 1 |
| Aortic disease | 3 | 3 | 19 |
| amyotrophic lateral sclerosis type 1 | 3 | 3 | 1 |
Top shared genes (genes linked to 2+ member diseases)
| Gene ⇵ | Member diseases ⇵ | Linked diseases |
|---|---|---|
| CAT | 5 / 6 | Acatalasia, Aortic disease, Bonnevie-ullrich syndrome, Turner syndrome and 1 more |
| SOD1 | 5 / 6 | amyotrophic lateral sclerosis type 1, Aortic disease, Bonnevie-ullrich syndrome, Turner syndrome and 1 more |
| SOD2 | 3 / 6 | Aortic disease, Bonnevie-ullrich syndrome, Turner syndrome |
| GH1 | 2 / 6 | Bonnevie-ullrich syndrome, Turner syndrome |
| IGFBP3 | 2 / 6 | Bonnevie-ullrich syndrome, Turner syndrome |
| NOS2 | 2 / 6 | Bonnevie-ullrich syndrome, Turner syndrome |
| VDR | 2 / 6 | Bonnevie-ullrich syndrome, Turner syndrome |
What do these columns mean?
- Connections in cluster
- How many other members this disease has a shared-gene link to (the node size in the network above). The most-connected diseases are the cluster's core.
- Significant partners
- How many of those links are statistically significant (FDR q < 0.05).
- Curated genes
- Distinct curated genes linked to that disease in GeDiPNet.
- Member diseases (Top shared genes)
- How many of this cluster's diseases are linked to the gene, out of the cluster's total. Genes shared by many members are the most direct explanation of why they group together.
- Overlap genes (x / y)
- x = genes shared between this cluster and the pathway/GO term; y = that pathway/GO term's total gene count. A higher x relative to y (and to the cluster's own size) means a tighter biological match.
- Cluster gene count
- Total distinct genes across every disease in this cluster -- the "n" used in the significance test below.
- Fold enrichment
- Observed overlap divided by the overlap expected by chance, given the cluster's gene count, the pathway/term's size and the gene universe tested. 5× means five times more shared genes than random. Tells strong hits apart when q-values are all vanishingly small.
- P-value / FDR q-value
- Is this pathway/GO term's overlap with the cluster more than chance? Upper-tail hypergeometric test, Benjamini-Hochberg corrected across every tested pathway/term (prefer the q-value -- it accounts for testing many at once).
- Shared genes (Pairs within this cluster)
- Number of curated genes the two diseases in that row have in common.
- Similarity score (Pairs within this cluster)
- Jaccard-based gene overlap between the two specific diseases in that row -- same metric as the main Shared-Gene Disease Pairs page.
Enriched Pathways (why this cluster is grouped, biologically)
| Pathway ⇵ | Source ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| Detoxification of Reactive Oxygen Species | Reactome | 5 / 34 | 67.9× | 8.43e-9 | 7.55e-7 ✓ sig. |
| Peroxisome | KEGG | 4 / 83 | 22.3× | 2.82e-5 | 7.92e-4 ✓ sig. |
| Pathways in cancer | KEGG | 7 / 533 | 6.1× | 1.03e-4 | 2.30e-3 ✓ sig. |
| Longevity regulating pathway - multiple species | KEGG | 3 / 62 | 22.4× | 3.13e-4 | 5.54e-3 ✓ sig. |
| Interleukin-4 and Interleukin-13 signaling | Reactome | 3 / 108 | 12.8× | 1.58e-3 | 1.92e-2 ✓ sig. |
| Activation of Matrix Metalloproteinases | Reactome | 2 / 33 | 28.0× | 2.28e-3 | 2.52e-2 ✓ sig. |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | Reactome | 3 / 125 | 11.1× | 2.40e-3 | 2.61e-2 ✓ sig. |
| Relaxin signaling pathway | KEGG | 3 / 130 | 10.7× | 2.69e-3 | 2.84e-2 ✓ sig. |
| FoxO signaling pathway | KEGG | 3 / 133 | 10.4× | 2.87e-3 | 2.98e-2 ✓ sig. |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | Reactome | 2 / 38 | 24.3× | 3.02e-3 | 3.09e-2 ✓ sig. |
| Fluid shear stress and atherosclerosis | KEGG | 3 / 141 | 9.8× | 3.38e-3 | 3.36e-2 ✓ sig. |
| Bladder cancer | KEGG | 2 / 41 | 22.5× | 3.51e-3 | 3.43e-2 ✓ sig. |
| EPH-ephrin mediated repulsion of cells | Reactome | 2 / 50 | 18.5× | 5.18e-3 | 4.47e-2 ✓ sig. |
| Collagen degradation | Reactome | 2 / 52 | 17.8× | 5.59e-3 | 4.71e-2 ✓ sig. |
| Inhibition of nitric oxide production | Reactome | 1 / 3 | 154× | 6.48e-3 | 5.19e-2 |
Enriched GO Terms (Biological Process, a second line of biological evidence)
| GO term ⇵ | GO ID ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| response to L-ascorbic acid | GO:0033591 | 3 / 4 | 539× | 9.56e-9 | 1.64e-6 ✓ sig. |
| response to reactive oxygen species | GO:0000302 | 4 / 20 | 144× | 1.40e-8 | 2.30e-6 ✓ sig. |
| response to hydrogen peroxide | GO:0042542 | 4 / 39 | 73.7× | 2.34e-7 | 2.47e-5 ✓ sig. |
| glutathione metabolic process | GO:0006749 | 4 / 49 | 58.7× | 5.98e-7 | 5.44e-5 ✓ sig. |
| response to hyperoxia | GO:0055093 | 3 / 14 | 154× | 8.62e-7 | 7.34e-5 ✓ sig. |
| superoxide metabolic process | GO:0006801 | 3 / 22 | 98.0× | 3.62e-6 | 2.32e-4 ✓ sig. |
| response to hypoxia | GO:0001666 | 5 / 176 | 20.4× | 3.92e-6 | 2.47e-4 ✓ sig. |
| response to nutrient levels | GO:0031667 | 4 / 79 | 36.4× | 4.12e-6 | 2.57e-4 ✓ sig. |
| response to estradiol | GO:0032355 | 4 / 84 | 34.2× | 5.27e-6 | 3.13e-4 ✓ sig. |
| response to superoxide | GO:0000303 | 2 / 5 | 287× | 1.86e-5 | 8.45e-4 ✓ sig. |
| response to xenobiotic stimulus | GO:0009410 | 5 / 248 | 14.5× | 2.07e-5 | 9.23e-4 ✓ sig. |
| extracellular matrix disassembly | GO:0022617 | 3 / 47 | 45.9× | 3.72e-5 | 1.44e-3 ✓ sig. |
| ovarian follicle development | GO:0001541 | 3 / 47 | 45.9× | 3.72e-5 | 1.44e-3 ✓ sig. |
| embryo implantation | GO:0007566 | 3 / 48 | 44.9× | 3.97e-5 | 1.51e-3 ✓ sig. |
| response to oxidative stress | GO:0006979 | 4 / 146 | 19.7× | 4.68e-5 | 1.71e-3 ✓ sig. |
Pairs within this cluster, by significance
| Disease A ⇵ | Disease B ⇵ | Similarity score ⇵ | Shared genes ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| Bonnevie-ullrich syndrome | Turner syndrome | 0.778 | 7 | 1.97e-25 | 5.17e-24 ✓ sig. |
| Aortic disease | Bonnevie-ullrich syndrome | 0.125 | 3 | 5.56e-8 | 4.28e-7 ✓ sig. |
| Aortic disease | Turner syndrome | 0.120 | 3 | 8.89e-8 | 6.59e-7 ✓ sig. |
| Bonnevie-ullrich syndrome | Ureteral calculi | 0.200 | 2 | 1.06e-6 | 6.56e-6 ✓ sig. |
| Turner syndrome | Ureteral calculi | 0.182 | 2 | 1.42e-6 | 8.55e-6 ✓ sig. |
| Aortic disease | Ureteral calculi | 0.091 | 2 | 8.64e-6 | 4.55e-5 ✓ sig. |
| Acatalasia | Ureteral calculi | 0.200 | 1 | 2.60e-4 | 6.40e-4 ✓ sig. |
| amyotrophic lateral sclerosis type 1 | Ureteral calculi | 0.200 | 1 | 2.60e-4 | 6.40e-4 ✓ sig. |
| Acatalasia | Bonnevie-ullrich syndrome | 0.125 | 1 | 4.55e-4 | 9.55e-4 ✓ sig. |
| amyotrophic lateral sclerosis type 1 | Bonnevie-ullrich syndrome | 0.125 | 1 | 4.55e-4 | 9.55e-4 ✓ sig. |
| Acatalasia | Turner syndrome | 0.111 | 1 | 5.20e-4 | 1.04e-3 ✓ sig. |
| amyotrophic lateral sclerosis type 1 | Turner syndrome | 0.111 | 1 | 5.20e-4 | 1.04e-3 ✓ sig. |